This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Nimble Epitech, LLC. Active years: 2013-2019.
Company Filing History:
Years Active: 2013-2019
Title: The Innovative Mind of Elliot M Epner
Introduction
Elliot M Epner is a prominent inventor based in Harrisburg, PA, renowned for his contributions to the field of pharmaceuticals. With two patents to his credit, Epner has shown a remarkable ability to innovate in the arena of cancer treatment through specialized pharmaceutical compositions.
Latest Patents
Elliot M Epner's latest patents focus on a pharmaceutical composition that combines a hypomethylating agent and a histone deacetylase inhibitor (HDAC inhibitor) for induction therapy. This composition includes a DNA and histone methylation inhibitor, such as cladribine, alongside HDAC inhibitors like entinostat, panobinostat, vorinostat, and romidepsin. The formulations created provide various methods of administration, including transdermal patches, oral dosage, and intravenous delivery, in combination with monoclonal antibodies aimed at treating various cancers, sarcomas, and other malignancies.
Career Highlights
Elliot Epner has made significant strides in his career as an inventor at Nimble Epitech, LLC. His innovative work in pharmaceutical compositions highlights his commitment to advancing cancer treatment methodologies. By successfully obtaining patents for these compositions, he establishes a foundation for further research and potential clinical applications.
Collaborations
Epner collaborates with fellow inventor Luke M Vaughan, showcasing a partnership that fosters creativity and innovation within the realm of pharmaceutical development. Their combined efforts contribute to the enhancement of therapeutic strategies targeting complex health issues.
Conclusion
Elliot M Epner is a distinguished figure in the pharmaceutical industry, whose inventive spirit and dedication to improving cancer therapies stand out. His contributions through patents speak to his expertise and commitment to innovation, furthering the potential for new treatment strategies that could significantly impact patient care.